Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

on. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.

    Conclusion

    - In virtually all patients with prostate cancer, tumor cells appear to
      express LHRH receptors;
    - Even tumors persisting or relapsing after castration or prolonged
      hormonal treatment with LHRH agonists retain the expression of LHRH
      receptors;
    - The continued expression of these receptors supports the concept of
      targeting prostatic LHRH receptors to deliver cytotoxic therapy based
      on LHRH analogs, such as AEZS-108.

A copy of the abstract is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/24/2014)... PHILADELPHIA , November 24, 2014 ... Reference Workflow, honored for dynamic leadership skills, business acumen ... scientific, technical and medical information products and services, congratulates ... Manager for Clinical Reference and Workflow, Elsevier Clinical Solutions, ... Women Worth Watching ® Awards issue of ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... 22, 2014 The “Chiral Chromatography ... by Material (Metal, Glass, Plastic), by Application [GC, ... - Forecast to 2018” analyses and studies the ... North America, Europe, Asia, and Rest of the ... 15 figures spread through 135 pages and in-depth ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... DJO Incorporated,(NYSE: DJO ), a global provider of ... reported that on August 9, 2007,the U.S. Federal Trade ... the Hart-Scott-Rodino Antitrust Improvements Act of,1976, as amended, for ... Therapeutics, Inc. ("ReAble"). On July 16, 2007, DJO ...
... Valeant Pharmaceuticals ... ... Biosciences,Inc. (Pink Sheets: ARDC) today announced that it has received the ... (NYSE: VRX ). In December 2006, Ardea Biosciences entered ...
... Shareholder Support for Vermed Sale, SAN DIEGO, Aug. ... innovator and leader of,impedance cardiography (ICG) technology, today announced ... progressing well with over 50%,of the necessary shareholder votes ... the Vermed sale. The ratio of votes,received is running ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
(Date:11/7/2014)... -- In conjunction with the Glendale and ... of the Verdugos has announced the " GLENDALE ... initiative to keep the Verdugo Regional Crime Lab operational after ... of existence, the Lab has processed more than 400 DNA ... "Because our number one priority is the wellbeing ...
(Date:11/6/2014)... team of Florida State University biologists could lead to ... and survive environmental swings such as droughts or floods. ... the journal The Plant Cell , sheds light ... is organized in a cell and how plants regulate ... and others are turned off. , "If you understand ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Maize analysis yields whole new world of genetic science 2
... Researchers at the Yerkes National Primate Research Center, ... prairie voles, an important step toward unlocking the ... application of this technology will enable scientists to ... help identify the brain mechanisms of social bonding ...
... This release is available in German . ... It contains loads of mitochondria, miniature power stations which among ... a voltage similar to that of a battery, which then provides ... have a short circuit. They go full steam ahead all the ...
... from the United States, the other from Canada, put the satellite ... Ellesmere Island, only 600 miles from the North Pole. Their goal ... in the long, dark days of winter in one of the ... in 2003," said David Mech, a renowned U.S. Geological Survey (USGS) ...
Cached Biology News:Yerkes researchers create first transgenic prairie voles 2Brown fat cells make 'spare tires' shrink 2North Pole wolf emails locations to researchers 2North Pole wolf emails locations to researchers 3
... caudal-related homeobox family, is an intestine-specific transcription ... in intestinal epithelial cells. It plays an ... phenotype of differentiated villus enterocytes as well ... Clone CDX2-88 reacts with a conserved epitope ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Biology Products: